

Massimo Gadina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1957065/publications.pdf>

Version: 2024-02-01

106
papers

18,520
citations

30070

54
h-index

25787

108
g-index

115
all docs

115
docs citations

115
times ranked

21270
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. <i>Cell</i> , 1999, 97, 133-144.	28.9	1,271
2	Activated STING in a Vascular and Pulmonary Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 507-518.	27.0	1,074
3	The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. <i>Annual Review of Medicine</i> , 2015, 66, 311-328.	12.2	1,074
4	Cytokine Signaling in 2002. <i>Cell</i> , 2002, 109, S121-S131.	28.9	978
5	An Autoinflammatory Disease with Deficiency of the Interleukin-1 Receptor Antagonist. <i>New England Journal of Medicine</i> , 2009, 360, 2426-2437.	27.0	892
6	JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 843-862.	46.4	759
7	JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. <i>Drugs</i> , 2017, 77, 521-546.	10.9	711
8	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. <i>New England Journal of Medicine</i> , 2014, 370, 911-920.	27.0	687
9	Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. <i>Nature Genetics</i> , 2010, 42, 698-702.	21.4	595
10	Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. <i>New England Journal of Medicine</i> , 2020, 383, 2628-2638.	27.0	580
11	Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). <i>Journal of Immunology</i> , 2011, 186, 4234-4243.	0.8	569
12	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. <i>Nature Genetics</i> , 2016, 48, 67-73.	21.4	513
13	Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2016, 12, 25-36.	8.0	468
14	Critical Role for STAT4 Activation by Type 1 Interferons in the Interferon- β Response to Viral Infection. <i>Science</i> , 2002, 297, 2063-2066.	12.6	443
15	Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. <i>Nature Immunology</i> , 2002, 3, 741-748.	14.5	422
16	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3041-3052.	8.2	387
17	Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. <i>Journal of Clinical Immunology</i> , 2003, 23, 147-161.	3.8	324
18	Super-enhancers delineate disease-associated regulatory nodes in T cells. <i>Nature</i> , 2015, 520, 558-562.	27.8	323

#	ARTICLE	IF	CITATIONS
19	Type 2 immunity in the skin and lungs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1582-1605.	5.7	304
20	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. <i>Journal of Clinical Investigation</i> , 2015, 125, 4196-4211.	8.2	258
21	Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes. <i>Journal of Immunology</i> , 2000, 164, 1768-1774.	0.8	228
22	Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10127-10132.	7.1	206
23	Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. <i>Nature</i> , 2020, 577, 103-108.	27.8	198
24	Signaling by Type I and II cytokine receptors: ten years after. <i>Current Opinion in Immunology</i> , 2001, 13, 363-373.	5.5	192
25	STAT4 serine phosphorylation is critical for IL-12-induced IFN- γ production but not for cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12281-12286.	7.1	192
26	Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. <i>Arthritis and Rheumatology</i> , 2017, 69, 148-160.	5.6	183
27	Inducible Expression of Stat4 in Dendritic Cells and Macrophages and Its Critical Role in Innate and Adaptive Immune Responses. <i>Journal of Immunology</i> , 2001, 166, 4446-4455.	0.8	172
28	Respiratory Syncytial Virus NS1 Protein Degrades STAT2 by Using the Elongin-Cullin E3 Ligase. <i>Journal of Virology</i> , 2007, 81, 3428-3436.	3.4	153
29	IL-12 Receptor $\beta 2$ (IL-12R $\beta 2$)-Deficient Mice Are Defective in IL-12-Mediated Signaling Despite the Presence of High Affinity IL-12 Binding Sites. <i>Journal of Immunology</i> , 2000, 165, 6221-6228.	0.8	147
30	Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. <i>Oncogene</i> , 2002, 21, 5097-5107.	5.9	140
31	Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. <i>Nature Genetics</i> , 2017, 49, 438-443.	21.4	129
32	Unexpected Effects of FERM Domain Mutations on Catalytic Activity of Jak3. <i>Molecular Cell</i> , 2001, 8, 959-969.	9.7	127
33	Somatic Mutations in <i>UBA1</i> Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. <i>Arthritis and Rheumatology</i> , 2021, 73, 1886-1895.	5.6	125
34	Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. <i>Journal of Leukocyte Biology</i> , 2018, 104, 499-514.	3.3	122
35	Development of a Validated Interferon Score Using NanoString Technology. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 171-185.	1.2	120
36	Whole Chromosome Instability induces senescence and promotes SASP. <i>Scientific Reports</i> , 2016, 6, 35218.	3.3	117

#	ARTICLE	IF	CITATIONS
37	Janus kinases to jakinibs: from basic insights to clinical practice. <i>Rheumatology</i> , 2019, 58, i4-i16.	1.9	111
38	Jakpot! New small molecules in autoimmune and inflammatory diseases. <i>Experimental Dermatology</i> , 2014, 23, 7-11.	2.9	105
39	A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: Description of two unrelated cases from Brazil. <i>Arthritis and Rheumatism</i> , 2011, 63, 4007-4017.	6.7	96
40	HijAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. <i>Science Immunology</i> , 2020, 5, .	11.9	94
41	Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 364-373.	4.7	93
42	Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. <i>Nature Communications</i> , 2021, 12, 3391.	12.8	93
43	Gi-Protein-Dependent Inhibition of IL-12 Production Is Mediated by Activation of the Phosphatidylinositol 3-Kinase-Protein 3 Kinase B/Akt Pathway and JNK. <i>Journal of Immunology</i> , 2005, 175, 2994-2999.	0.8	89
44	A Study of the Intracellular Routing of Cytotoxic Ribonucleases. <i>Journal of Biological Chemistry</i> , 1995, 270, 17476-17481.	3.4	86
45	The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders. <i>BioDrugs</i> , 2013, 27, 431-438.	4.6	84
46	Cytokines and their role in lymphoid development, differentiation and homeostasis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2002, 2, 495-506.	2.3	81
47	The Docking Molecule Gab2 Is Induced by Lymphocyte Activation and Is Involved in Signaling by Interleukin-2 and Interleukin-15 but Not Other Common Î³ Chain-using Cytokines. <i>Journal of Biological Chemistry</i> , 2000, 275, 26959-26966.	3.4	75
48	USP17 Regulates Ras Activation and Cell Proliferation by Blocking RCE1 Activity. <i>Journal of Biological Chemistry</i> , 2009, 284, 9587-9595.	3.4	72
49	Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. <i>Journal of Autoimmunity</i> , 2017, 85, 20-31.	6.5	67
50	Selective Janus kinase inhibitors come of age. <i>Nature Reviews Rheumatology</i> , 2019, 15, 74-75.	8.0	64
51	Cytokine regulation of IL-12 receptor Î²2 expression: differential effects on human T and NK cells. <i>European Journal of Immunology</i> , 2000, 30, 1364-1374.	2.9	63
52	Reversal of CD8 T-Cell-Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib. <i>Journal of Investigative Dermatology</i> , 2014, 134, 992-1000.	0.7	61
53	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 911-925.	2.9	57
54	Second Case of HOIP Deficiency Expands Clinical Features and Defines Inflammatory Transcriptome Regulated by LUBAC. <i>Frontiers in Immunology</i> , 2019, 10, 479.	4.8	54

#	ARTICLE	IF	CITATIONS
55	Kinase inhibitors in the treatment of immune-mediated disease. <i>F1000 Medicine Reports</i> , 2012, 4, 5.	2.9	53
56	SnapShot: Jak-STAT Signaling II. <i>Cell</i> , 2020, 181, 1696-1696.e1.	28.9	53
57	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 406-408.	0.9	53
58	Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. <i>International Journal of Immunopharmacology</i> , 1992, 14, 1045-1050.	1.1	51
59	<scp>JAK</scp>/<scp>STAT</scp> signaling in regulation of innate lymphoid cells: The gods before the guardians. <i>Immunological Reviews</i> , 2018, 286, 148-159.	6.0	51
60	Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Bloodâ€ Brain Barrier Function in Neonatalâ€ Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatalâ€ Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. <i>Arthritis and Rheumatology</i> , 2017, 69, 1325-1336.	5.6	50
61	Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 612-619.	0.9	49
62	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , 2021, 51, 1615-1627.	2.9	49
63	Targeting cytokine signaling in autoimmunity: back to the future and beyond. <i>Current Opinion in Immunology</i> , 2016, 43, 89-97.	5.5	47
64	Translating JAKs to Jakinibs. <i>Journal of Immunology</i> , 2020, 204, 2011-2020.	0.8	46
65	Viral FLIP Impairs Survival of Activated T Cells and Generation of CD8+ T Cell Memory. <i>Journal of Immunology</i> , 2004, 172, 6313-6323.	0.8	45
66	Cytokine Signaling: Birth of a Pathway. <i>Journal of Immunology</i> , 2011, 187, 5475-5478.	0.8	44
67	Cytokines and Cytokine Receptors. , 2019, , 127-155.e1.		44
68	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. <i>Arthritis and Rheumatology</i> , 2021, 73, 2166-2178.	5.6	43
69	CXCL12 Signaling Is Independent of Jak2 and Jak3. <i>Journal of Biological Chemistry</i> , 2005, 280, 17408-17414.	3.4	40
70	Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2625-2629.	7.1	39
71	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. <i>Arthritis Research and Therapy</i> , 2020, 22, 69.	3.5	39
72	Editorial: Decernotinib: A Nextâ€ Generation Jakinib. <i>Arthritis and Rheumatology</i> , 2016, 68, 31-34.	5.6	38

#	ARTICLE	IF	CITATIONS
73	Brief Report: Deficiency of Complement 1r Subcomponent in Early-Onset Systemic Lupus Erythematosus: The Role of Disease-Modifying Alleles in a Monogenic Disease. <i>Arthritis and Rheumatology</i> , 2017, 69, 1832-1839.	5.6	38
74	Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation. <i>Molecular and Cellular Biology</i> , 2000, 20, 4371-4380.	2.3	35
75	ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. <i>Cytokine</i> , 2001, 15, 27-38.	3.2	32
76	Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery. <i>Immunity</i> , 2021, 54, 721-736.e10.	14.3	30
77	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. <i>Nature Communications</i> , 2021, 12, 4447.	12.8	30
78	Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2013, 16, S70-S72.	0.8	29
79	JAK1: Number one in the family; number one in inflammation?. <i>Rheumatology</i> , 2021, 60, ii3-ii10.	1.9	28
80	Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver. <i>European Journal of Immunology</i> , 2021, 51, 2568-2575.	2.9	28
81	EAACI Biologicals Guidelines"dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	5.7	24
82	Cytohesin Binder and Regulator (Cybr) Is Not Essential for T- and Dendritic-Cell Activation and Differentiation. <i>Molecular and Cellular Biology</i> , 2006, 26, 6623-6632.	2.3	18
83	Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. <i>Clinical Rheumatology</i> , 2017, 36, 143-154.	2.2	17
84	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. <i>JCI Insight</i> , 2019, 4, .	5.0	17
85	Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. <i>Pharmaceuticals</i> , 2022, 15, 48.	3.8	16
86	Preclinical evaluation of the ribosome-inactivating proteins PAP-1, PAP-S and RTA in mice. <i>International Journal of Immunopharmacology</i> , 1995, 17, 829-839.	1.1	15
87	Advances in kinase inhibition. <i>Current Opinion in Rheumatology</i> , 2014, 26, 237-243.	4.3	15
88	HijAKing Innate Lymphoid Cells?. <i>Frontiers in Immunology</i> , 2017, 8, 438.	4.8	14
89	Germline gain-of-function myeloid differentiation primary response gene"88 (MYD88) mutation in a child with severe arthritis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1943-1947.e9.	2.9	14
90	New interleukins: are there any more?. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 211-217.	3.1	13

#	ARTICLE	IF	CITATIONS
91	Cytohesin Binder and Regulator Augments T Cell Receptor-induced Nuclear Factor of Activated T Cells-AP-1 Activation through Regulation of the JNK Pathway. <i>Journal of Biological Chemistry</i> , 2006, 281, 19985-19994.	3.4	13
92	Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 309-319.	3.0	12
93	Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. <i>Molecular Vision</i> , 2020, 26, 641-651.	1.1	10
94	Ubiquitination for activation: new directions in the NF-kappaB roadmap. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2004, 4, 144-6.	3.4	9
95	Transcriptional, Epigenetic and Pharmacological Control of JAK/STAT Pathway in NK Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2456.	4.8	8
96	183â€¦A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus. , 2019, , .		8
97	High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis. <i>Journal of Immunological Methods</i> , 2020, 477, 112667.	1.4	8
98	Cytokines and cytokine receptors. , 2013, , 108-135.		8
99	Immunodeficiency Is A Tough Nut to CRAC: The Importance of Calcium Flux in T Cell Activation. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2006, 6, 253-256.	3.4	8
100	Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	6
101	JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis. <i>Frontiers in Immunology</i> , 2019, 10, 2972.	4.8	6
102	Immune modulation: Turncoat regulatory T cells. <i>Nature Medicine</i> , 2009, 15, 1365-1365.	30.7	4
103	A173: Cerebrospinal Fluid Cytokines Correlate With Innate Immune Cells in Neonatal Onset Multisystem Inflammatory Disease (NOMID) Patients in Clinical Remission Treated With Anakinra. <i>Arthritis and Rheumatology</i> , 2014, 66, S226-S226.	5.6	4
104	Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report. <i>Pediatric Rheumatology</i> , 2021, 19, 54.	2.1	4
105	Protein Kinase Antagonists in Therapy of Immunological and Inflammatory Diseases. , 2019, , 1185-1196.e1.		2
106	Abstract 3023: The antitumor activity of immunotoxins is enhanced by tofacitinib. <i>Cancer Research</i> , 2017, 77, 3023-3023.	0.9	1